After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Enliven Therapeutics Inc is $1.49B. A total of 1.37 million shares were traded on the day, compared to an average of 859.82K shares.
In the most recent transaction, Lyssikatos Joseph P sold 91,198 shares of ELVN for 27.22 per share on Jan 09 ’26. After the transaction, the CHIEF SCIENTIFIC OFFICER now owns 765,188 company shares. In a previous transaction on Jan 08 ’26, Lyssikatos Joseph P sold 41,302 shares at 24.05 per share. ELVN shares that CHIEF SCIENTIFIC OFFICER owns now total 856,386.
Among the insiders who sold shares, Heyman Richard A. disposed of 9,635 shares on Jan 08 ’26 at a per-share price of $25.03. This resulted in the Director holding 25,545 shares of ELVN after the transaction. In another insider transaction, Heyman Richard A. sold 4,285 shares at $25.00 per share on Jan 09 ’26. Company shares held by the Director now total 25,107.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ELVN has a high of $29.98 and a low of $13.30.
As of this writing, ELVN has an earnings estimate of -$0.47 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of -$0.45 per share and a lower estimate of -$0.5. The company reported an EPS of -$0.46 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ELVN’s latest balance sheet shows that the firm has $110.02M in Cash & Short Term Investments as of fiscal 2021. There were $159.00k in debt and $5.75M in liabilities at the time. Its Book Value Per Share was $8.03, while its Total Shareholder’s Equity was -$42.89M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock.
